What is BioSig Technologies, Inc.'s equity method investments?

BioSig Technologies, Inc. (STEX) reported equity method investments of $33K in Q1 2026.

What does equity method investments mean?

Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.

BioSig Technologies, Inc. STEX Equity Method Investments

Equity Method Investments at other companies

Tradeweb Markets Inc.TW

$24.1M+35.4%

Bio-Rad LaboratoriesBIO

$23.7M+3.0%

WisdomTreeWT

$28.62M+210%

ROP

Roper Technologies, Inc.ROP

$963.6M+32.3%

MedtronicMDT

——

Other financials

Income statement

See full

Revenue$13.0K+8.3%

Gross profit$12.0K-88.9%

Operating income-$35.7M-1,098%

Net income-$46.7M-1,560%

EPS (diluted)-$0.27-92.9%

Balance sheet

See full

Cash & equivalents$6.9M+84.0%

Total debt$15.0K-94.7%

Total equity$159.0M+6,003%

Total assets$173.3M+3,823%

Cash flow

See full

Operating cash flow-$10.2M-813%

CapEx$4.0K-93.1%

Free cash flow-$2.9M+29.4%

Valuation

See full

Market cap$88.66M-61.8%

P/S2,216.6×-5,967×

Profitability

See full

Gross margin80.1%+25.2pp

Operating margin-32,155%-14,261pp

Net margin-25,825%-11,789pp

FCF margin-97,216.7%-106,293pp

Returns & leverage

See full

Return on equity-627.1%—

Debt / equity0×—

Current ratio13.9×+11.5×

Where this comes from

Reported directly by BioSig Technologies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermInvestments.

The official record: BioSig Technologies, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioSig Technologies, Inc.'s equity method investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioSig Technologies, Inc.'s equity method investments?: BioSig Technologies, Inc. (STEX) reported equity method investments of $33K in Q1 2026.
What does equity method investments mean?: Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.